SCHEDULE 13G: State Street Corporation Discloses 4.3% Passive Stake in Twist Bioscience Corp

State Street Corporation has filed a Schedule 13G, reporting a 4.3% beneficial ownership stake in Twist Bioscience Corp as of December 31, 2024.

Summary

• State Street Corporation, a parent holding company, reported beneficial ownership of 2,543,997 shares of common stock in Twist Bioscience Corp.
• This represents 4.3% of the outstanding common stock of Twist Bioscience Corp.
• The filing indicates that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• State Street Corporation holds shared voting power over 2,314,792 shares and shared dispositive power over 2,543,997 shares.
• The beneficial ownership is held through various investment adviser subsidiaries, including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, State Street Global Advisors, Australia, Limited, and State Street Global Advisors, Ltd.

Sentiment

Score: 5

Explanation: Neutral. This is a routine disclosure of passive institutional ownership and does not contain positive or negative operational or financial news about the issuer.

Positives

• State Street Corporation's passive investment indicates a belief in the long-term value of Twist Bioscience Corp without seeking control.
• The filing confirms the shares are held in the ordinary course of business, suggesting a standard portfolio investment rather than an activist stance.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding Twist Bioscience Corp's future outlook or State Street Corporation's investment strategy beyond the passive nature of the holding.

Management Comments

• The filing includes a certification by State Street Corporation that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing reflects a standard institutional investment by a major financial services company, State Street Corporation, in a biotechnology firm, Twist Bioscience Corp. Such passive stakes are common for large asset managers who invest across various industries, including the high-growth biotechnology sector, as part of diversified portfolios.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily serves as a disclosure of passive ownership by a large institutional investor. It does not provide operational or financial results for Twist Bioscience Corp that would allow for direct comparison to industry-specific benchmarks or competitor performance.
• The 4.3% stake is below the 5% threshold that would typically trigger more detailed Schedule 13D filings, indicating a non-activist investment approach, which is standard for many large asset managers like State Street Corporation.

Stakeholder Impact

• Shareholders of Twist Bioscience Corp: The disclosure of a significant institutional holder like State Street Corporation can provide a degree of stability and confidence, indicating institutional interest in the company's stock.

Key Dates

Keywords

Twist Bioscience Corp, State Street Corporation, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Passive Investment, Biotechnology, Synthetic Biology